Antipodes Partners LTD Vertex Pharmaceuticals Inc Transaction History
Antipodes Partners LTD
- $2.83 Billion
- Q3 2024
A detailed history of Antipodes Partners LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Antipodes Partners LTD holds 127,853 shares of VRTX stock, worth $57.7 Million. This represents 2.1% of its overall portfolio holdings.
Number of Shares
127,853
Previous 127,295
0.44%
Holding current value
$57.7 Million
Previous $59.7 Million
0.34%
% of portfolio
2.1%
Previous 2.2%
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,721Shares Held
222MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$12.1 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.5 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.62 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.33 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.06 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $116B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...